Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

For the second time in less than a year, doctors at Massachusetts General Hospital have transplanted a genetically-edited pig ...

Examples of selflessness are hard to find in today’s world.However, there are still some people in the world who think of ...

A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...

ONE of the main diseases that lifestyle contributes to is diabetes which leads to kidney disease, says Dr Robin Sios.

Sambalpur: The number of kidney patients is on the rise in Bargarh district due to use of pesticides in agriculture, ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

When it comes to the potential of H5N1 avian flu, otherwise known as bird flu, picking up mutations that may lead to human-to ...